Related Experiment Video

Updated: Jun 29, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Deletions of CDKN2C in multiple myeloma: biological and clinical implications

Paola E Leone1, Brian A Walker, Matthew W Jenner

  • 1Section of Haemato-Oncology, The Institute of Cancer Research, 15 Cotswold Road, London, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 3, 2008
PubMed
Abstract

Insights

Deletions in the CDKN2C gene on chromosome 1 are linked to worse overall survival in multiple myeloma patients. These deletions also correlate with increased myeloma cell proliferation.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Chromosome 1 deletions are observed in multiple myeloma with unclear clinical significance.
  • The CDKN2C gene at 1p32.3 is a potential target of these deletions.

Purpose of the Study:

  • To investigate the clinical impact of 1p deletions in multiple myeloma.
  • To define the role of CDKN2C in primary patient samples using high-resolution techniques.

Main Methods:

  • Fluorescence in situ hybridization (FISH) was used to detect CDKN2C deletions in 515 cases (MGUS, SMM, multiple myeloma).
  • Affymetrix SNP mapping and expression arrays were performed on 78 myeloma cases.
  • Mutation, methylation, and Western blot analyses were also conducted.

Main Results:

  • CDKN2C deletion was identified in 4.5% of MGUS, 10.3% of SMM, and 15% of multiple myeloma cases.
  • Patients with hemizygous or homozygous CDKN2C deletion had significantly worse overall survival (22 vs. 38 months, P=0.003).
  • Homozygous CDKN2C deletions resulted in complete loss of gene expression and were associated with the most proliferative myelomas.

Conclusions:

  • CDKN2C deletions are significant in the progression of multiple myeloma.
  • The status of CDKN2C impacts clinical outcomes in myeloma patients.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...